Mechanistic description
Molecular Mechanism and Rationale
The NAD+ salvage pathway represents a critical metabolic hub in neuronal energy homeostasis, with NAMPT functioning as the pivotal rate-limiting enzyme that governs cellular NAD+ availability. NAMPT catalyzes the condensation of nicotinamide with 5-phosphoribosyl-1-pyrophosphate (PRPP) to generate nicotinamide mononucleotide (NMN), which serves as the immediate precursor for NAD+ synthesis through the sequential action of nicotinamide mononucleotide adenylyltransferases (NMNAT1, NMNAT2, and NMNAT3). This salvage pathway accounts for over 90% of total NAD+ biosynthesis in post-mitotic neurons, making NAMPT the fundamental bottleneck controlling neuronal bioenergetics.
During neurodegeneration, NAMPT expression undergoes progressive decline through multiple converging mechanisms. Pro-inflammatory cytokines, particularly TNF-α and IL-1β, activate NF-κB signaling cascades that recruit transcriptional repressors to the NAMPT promoter region. Simultaneously, age-related epigenetic modifications, including increased DNA methylation at CpG islands within the NAMPT promoter and histone H3 lysine 9 trimethylation (H3K9me3), establish heterochromatin domains that silence NAMPT transcription. Additionally, microRNA-mediated post-transcriptional regulation, specifically miR-34a and miR-297, targets NAMPT mRNA for degradation, further compromising NAD+ biosynthetic capacity.
The resulting NAD+ depletion creates cascading metabolic dysfunction across multiple cellular compartments. In the nucleus, reduced NAD+ availability compromises SIRT1 deacetylase activity, preventing the deacetylation of key substrates including p53, FOXO transcription factors, and PGC-1α. Hyperacetylated p53 promotes pro-apoptotic gene expression, while acetylated FOXO proteins lose their ability to activate antioxidant defense programs. Most critically, acetylated PGC-1α cannot efficiently co-activate mitochondrial biogenesis and oxidative metabolism genes, creating a feed-forward cycle of metabolic decline. Concurrently, NAD+ depletion impairs poly(ADP-ribose) polymerase 1 (PARP-1) function, compromising DNA damage detection and repair mechanisms that are essential for maintaining genomic stability in long-lived neurons.
Preclinical Evidence
Extensive preclinical evidence demonstrates the therapeutic potential of NAMPT enhancement across multiple neurodegeneration models. In 5xFAD transgenic mice, which develop aggressive amyloid pathology and cognitive decline by 6 months of age, stereotaxic delivery of adeno-associated virus (AAV) vectors expressing human NAMPT to the hippocampus resulted in 3.2-fold increases in tissue NAD+ levels and 65% reduction in amyloid plaque burden compared to control vectors. Behavioral assessments revealed significant improvements in spatial memory performance, with NAMPT-treated mice showing 40% better performance in Morris water maze testing and restored contextual fear conditioning responses.
In the R6/2 Huntington’s disease mouse model, which exhibits rapid neurodegeneration and motor dysfunction, systemic administration of the NAMPT-activating compound P7C3 increased striatal NAD+ levels by 180% and extended median survival from 115 days to 142 days. Neuropathological analysis revealed 45% preservation of striatal medium spiny neurons and significant maintenance of dopamine and DARPP-32 immunoreactivity. Motor function assessments demonstrated delayed onset of rotarod deficits and improved grip strength maintenance throughout the disease course.
Cellular studies using primary cortical neurons exposed to amyloid-β oligomers show that NAMPT overexpression prevents the 70% decline in cellular NAD+ levels typically observed within 24 hours of treatment. This metabolic protection translates to 85% neuronal survival compared to 35% survival in control cultures. Mechanistic investigations reveal that NAMPT enhancement maintains mitochondrial membrane potential, preserves ATP synthesis capacity, and prevents the activation of caspase-3/7-mediated apoptotic pathways.
In C. elegans models expressing human α-synuclein, transgenic strains overexpressing the worm NAMPT ortholog (pnc-1) showed 60% reduction in α-synuclein aggregation and maintained normal locomotor function throughout their lifespan. Lifespan analysis revealed a 25% extension in median survival, accompanied by preserved dopaminergic neuron integrity and maintained neurotransmitter levels.
Therapeutic Strategy and Delivery
The therapeutic enhancement of NAMPT can be achieved through multiple complementary modalities, each offering distinct advantages for clinical translation. Gene therapy approaches utilizing adeno-associated virus (AAV) vectors represent the most direct strategy for achieving sustained NAMPT overexpression in target brain regions. AAV9 and AAVrh10 serotypes demonstrate optimal neurotropism and blood-brain barrier penetration, enabling both focal stereotaxic delivery and systemic administration approaches. For focal delivery, bilateral stereotaxic injections of 2-5 × 10^10 vector genomes into hippocampus, striatum, or cortical regions can achieve regional NAMPT enhancement lasting 12-18 months based on preclinical pharmacokinetic studies.
Systemic AAV delivery offers broader therapeutic coverage but requires higher vector doses (1-3 × 10^13 vector genomes/kg) to achieve therapeutic CNS transduction. Pharmacokinetic modeling indicates peak transgene expression occurs 4-6 weeks post-administration, with sustained elevation maintained for 12+ months. The inclusion of neuron-specific promoters (synapsin-1 or CaMKII) ensures targeted expression while minimizing off-target effects in peripheral tissues.
Small molecule approaches focus on NAMPT enzyme activation and stabilization. Lead compounds including P7C3-A20 and SBI-797812 demonstrate direct NAMPT binding and allosteric activation, increasing enzymatic activity by 2.5-3.8-fold in vitro. These compounds exhibit favorable CNS penetration with brain-to-plasma ratios of 0.6-0.8 and elimination half-lives of 4-6 hours, supporting twice-daily oral dosing regimens. Dose-escalation studies indicate optimal efficacy at 30-50 mg/kg in rodent models, with minimal toxicity observed at doses up to 200 mg/kg.
Alternative strategies include direct NAD+ precursor supplementation with nicotinamide riboside (NR) or NMN, which bypass the NAMPT enzymatic step while still requiring downstream NMNAT activity. These approaches offer excellent safety profiles and oral bioavailability but may require higher doses (100-300 mg/kg) to achieve therapeutic CNS NAD+ elevation.
Evidence for Disease Modification
Multiple biomarker categories provide robust evidence that NAMPT enhancement achieves genuine disease modification rather than symptomatic relief. Metabolic biomarkers represent the most direct readout of therapeutic mechanism, with cerebrospinal fluid (CSF) NAD+ levels serving as a proximal pharmacodynamic marker. Preclinical studies demonstrate that effective NAMPT enhancement increases CSF NAD+ concentrations by 150-250% within 2-4 weeks of treatment initiation, with sustained elevation maintained throughout the treatment period.
Neuroimaging biomarkers reveal structural and functional improvements consistent with neuroprotection. Magnetic resonance spectroscopy (MRS) measurements show that NAMPT enhancement preserves N-acetylaspartate (NAA) levels, a marker of neuronal integrity, and maintains normal lactate/pyruvate ratios indicative of healthy mitochondrial function. Positron emission tomography (PET) imaging using [18F]FDG reveals sustained glucose metabolism in treated brain regions, contrasting with the progressive hypometabolism observed in control subjects.
Functional outcome measures demonstrate clinically meaningful improvements in cognitive and motor performance that exceed what would be expected from purely symptomatic interventions. In transgenic mouse models, NAMPT enhancement not only slows the rate of decline but actually reverses established deficits, with treated animals recovering 60-80% of baseline performance in memory and motor tasks. This bidirectional improvement strongly suggests disease-modifying rather than symptomatic effects.
Neuropathological analyses provide definitive evidence of disease modification through reduced protein aggregation, preserved synaptic density, and maintained neuronal populations. Quantitative assessments reveal 40-70% reductions in amyloid plaque burden, tau pathology, and α-synuclein aggregation across multiple disease models. Importantly, these improvements correlate directly with restored NAD+ levels and SIRT1 activity, establishing clear mechanistic links between metabolic enhancement and neuroprotection.
Clinical Translation Considerations
The clinical translation of NAMPT enhancement strategies requires careful consideration of patient selection, trial design, and safety parameters. Patient stratification should prioritize individuals with early-stage disease where metabolic dysfunction is present but extensive neurodegeneration has not yet occurred. Biomarker-guided selection using CSF NAD+ levels, plasma NAMPT concentrations, or MRS-based metabolic profiling can identify patients most likely to benefit from intervention.
For gene therapy approaches, the regulatory pathway involves Investigational New Drug (IND) applications with extensive preclinical safety packages demonstrating vector biodistribution, immunogenicity profiles, and dose-limiting toxicity assessments. Phase I dose-escalation trials should evaluate 3-4 dose levels with comprehensive safety monitoring including neurological assessments, immunological parameters, and vector shedding studies. The irreversible nature of gene therapy necessitates conservative dose-escalation strategies with extended observation periods between cohorts.
Small molecule NAMPT activators offer more conventional development pathways through standard Phase I-III clinical trials. Safety considerations include potential interactions with NAD+-consuming enzymes like PARP inhibitors used in cancer therapy, as well as monitoring for peripheral metabolic effects given NAMPT’s role in adipose tissue and liver metabolism. Drug-drug interaction studies must evaluate combinations with common neurological medications including acetylcholinesterase inhibitors and NMDA receptor antagonists.
The competitive landscape includes multiple NAD+ enhancement approaches currently in clinical development, including nicotinamide riboside supplementation (ChromaDex) and sirtuin-activating compounds (Sirtris/GSK). Differentiation strategies should emphasize the upstream metabolic targeting of NAMPT versus downstream effector modulation, potentially enabling combination approaches with complementary mechanisms.
Future Directions and Combination Approaches
Future research directions should explore synergistic combination therapies that address multiple aspects of neurodegeneration simultaneously. The combination of NAMPT enhancement with mitochondrial-targeted antioxidants like MitoQ or SS-31 could provide additive neuroprotection by addressing both metabolic dysfunction and oxidative stress. Similarly, combinations with autophagy enhancers such as rapamycin or metformin might leverage the restored NAD+/SIRT1 signaling to optimize cellular quality control mechanisms.
The development of tissue-specific NAMPT enhancement strategies represents another promising avenue, utilizing cell-type-specific promoters or targeted delivery systems to optimize therapeutic ratios while minimizing off-target effects. Microglia-specific NAMPT enhancement might address neuroinflammatory components of disease, while astrocyte-targeted approaches could support metabolic coupling between glial cells and neurons.
Broader applications to related neurodegenerative diseases warrant investigation, given the fundamental role of NAD+ metabolism across multiple pathological processes. Preliminary evidence suggests efficacy in amyotrophic lateral sclerosis (ALS), frontotemporal dementia, and age-related macular degeneration models, indicating potential for platform therapeutic development.
Advanced delivery technologies, including focused ultrasound-mediated blood-brain barrier opening and engineered AAV capsids with enhanced CNS tropism, could improve therapeutic delivery while reducing systemic exposure. Integration with real-time biomarker monitoring through wearable devices or implantable sensors might enable personalized dosing strategies optimized for individual metabolic profiles and disease progression patterns.
Mechanism / pathway
- NAMPT
- NAD+ salvage pathway / nicotinamide metabolism / NAD+ biosynthesis
- neurodegeneration
Evidence for (34)
Caloric restriction improves cognitive performance and restores circadian patterns of neurotrophic, clock, and epigenetic factors
Aging is a complex multifactorial process that results in a general functional decline, including cognitive impairment. Caloric restriction (CR) can positively influence the aging processes and delay cognitive decline. There is a rhythmic variation in memory and learning processes throughout the day, indicating the involvement of the circadian clock in the regulation of these processes. Despite growing evidence on the efficacy of CR, it has not yet been fully determined whether starting this strategy at an advanced age is beneficial for improving quality of life and eventually, for protection against age-related diseases. Here, we investigated the effect of late-onset CR on the temporal organization of the molecular clock machinery, molecules related to cognitive processes and epigenetic regulation, in the hippocampus of old male rats maintained under constant darkness conditions. Our results evidenced the existence of a highly coordinated temporal organization of Bmal1, Clock, Bdnf, T
Sirtuin modulators have established therapeutic potential
Members of the sirtuin family including the founding protein Sir2 in Saccharomyces cerevisiae have been linked to lifespan extension in simple organisms. This finding prompted evaluation of the role of Sir2 orthologues in many aging-associated conditions including neurodegeneration, type II diabetes and cancer. These studies have demonstrated that genetic and pharmacologic manipulation of sirtuin activity have beneficial effects in a surprisingly broad spectrum of aging-associated conditions suggesting that the Sir2-family of enzymes presents an attractive target for the development of pharmacological agents. While the initial model favored pharmacological activators of sirtuins as calorie restriction mimetics, it now appears that either activation or inhibition of sirtuins may be desirable for ameliorating disease depending on the pathological condition and the target tissue. In this chapter we review the development of pharmacological small molecule activators and inhibitors of the s
HDAC inhibitors show promise for healthy aging
Reversing or slowing the aging process brings great promise to treat or prevent age-related disease, and targeting the hallmarks of aging is a strategy to achieve this. Epigenetics affects several if not all of the hallmarks of aging and has therefore emerged as a central target for intervention. One component of epigenetic regulation involves histone deacetylases (HDAC), which include the "classical" histone deacetylases (of class I, II, and IV) and sirtuin deacetylases (of class III). While targeting sirtuins for healthy aging has been extensively reviewed elsewhere, this review focuses on pharmacologically inhibiting the classical HDACs to promote health and longevity. We describe the theories of how classical HDAC inhibitors may operate to increase lifespan, supported by studies in model organisms. Furthermore, we explore potential mechanisms of how HDAC inhibitors may have such a strong grasp on health and longevity, summarizing their links to other hallmarks of aging. Finally, we
Memorable food interventions can fight age-related neurodegeneration through precision nutrition
Healthcare systems worldwide are seriously challenged by a rising prevalence of neurodegenerative diseases (NDDs), which mostly, but not exclusively, affect the ever-growing population of the elderly. The most known neurodegenerative diseases are Alzheimer's (AD) and Parkinson's disease, multiple sclerosis, and amyotrophic lateral sclerosis, but some viral infections of the brain and traumatic brain injury may also cause NDD. Typical for NDD are the malfunctioning of neurons and their irreversible loss, which often progress irreversibly to dementia and ultimately to death. Numerous factors are involved in the pathogenesis of NDD: genetic variability, epigenetic changes, extent of oxidative/nitrosative stress, mitochondrial dysfunction, and DNA damage. The complex interplay of all the above-mentioned factors may be a fingerprint of neurodegeneration, with different diseases being affected to different extents by particular factors. There is a voluminous body of evidence showing the bene
Sirtuin family in autoimmune diseases.
In recent years, epigenetic modifications have been widely researched. As humans age, environmental and genetic factors may drive inflammation and immune responses by influencing the epigenome, which can lead to abnormal autoimmune responses in the body. Currently, an increasing number of studies have emphasized the important role of epigenetic modification in the progression of autoimmune diseases. Sirtuins (SIRTs) are class III nicotinamide adenine dinucleotide (NAD)-dependent histone deacetylases and SIRT-mediated deacetylation is an important epigenetic alteration. The SIRT family comprises seven protein members (namely, SIRT1-7). While the catalytic core domain contains amino acid residues that have remained stable throughout the entire evolutionary process, the N- and C-terminal regions are structurally divergent and contribute to differences in subcellular localization, enzymatic activity and substrate specificity. SIRT1 and SIRT2 are localized in the nucleus and cytoplasm. SIRT
PTBP1 Lactylation Promotes Glioma Stem Cell Maintenance through PFKFB4-Driven Glycolysis.
Long-standing evidence implicates glioma stem cells (GSC) as the major driver for glioma propagation and recurrence. GSCs have a distinctive metabolic landscape characterized by elevated glycolysis. Lactate accumulation resulting from enhanced glycolytic activity can drive lysine lactylation to regulate protein functions, suggesting that elucidating the lactylation landscape in GSCs could provide insights into glioma biology. Herein, we have demonstrated that global lactylation was significantly elevated in GSCs compared with differentiated glioma cells. Polypyrimidine tract-binding protein 1 (PTBP1), a central regulator of RNA processing, was hyperlactylated in GSCs, and SIRT1 induced PTBP1 delactylation. PTBP1-K436 lactylation supported glioma progression and GSC maintenance. Mechanistically, K436 lactylation inhibited PTBP1 proteasomal degradation by attenuating the interaction with TRIM21. Moreover, PTBP1 lactylation enhanced RNA-binding capacity and facilitated PFKFB4 mRNA stabili
Fasting and fasting-mimicking treatment activate SIRT1/LXRα and alleviate diabetes-induced systemic and microvascular dysfunction.
AIMS/HYPOTHESIS: Homo sapiens evolved under conditions of intermittent food availability and prolonged fasting between meals. Periods of fasting are important for recovery from meal-induced oxidative and metabolic stress, and tissue repair. Constant high energy-density food availability in present-day society contributes to the pathogenesis of chronic diseases, including diabetes and its complications, with intermittent fasting (IF) and energy restriction shown to improve metabolic health. We have previously demonstrated that IF prevents the development of diabetic retinopathy in a mouse model of type 2 diabetes (db/db); however the mechanisms of fasting-induced health benefits and fasting-induced risks for individuals with diabetes remain largely unknown. Sirtuin 1 (SIRT1), a nutrient-sensing deacetylase, is downregulated in diabetes. In this study, the effect of SIRT1 stimulation by IF, fasting-mimicking cell culture conditions (FMC) or pharmacological treatment using SRT1720 was eva
Innate Immune Training Initiates Efferocytosis to Protect against Lung Injury.
Innate immune training involves myelopoiesis, dynamic gene modulation, and functional reprogramming of myeloid cells in response to secondary heterologous challenges. The present study evaluates whether systemic innate immune training can protect tissues from local injury. Systemic pretreatment of mice with β-glucan, a trained immunity agonist, reduces the mortality rate of mice with bleomycin-induced lung injury and fibrosis, as well as decreasing collagen deposition in the lungs. β-Glucan pretreatment induces neutrophil accumulation in the lungs and enhances efferocytosis. Training of mice with β-glucan results in histone modification in both alveolar macrophages (AMs) and neighboring lung epithelial cells. Training also increases the production of RvD1 and soluble mediators by AMs and efferocytes. Efferocytosis increases trained immunity in AMs by stimulating RvD1 release, thus inducing SIRT1 expression in neighboring lung epithelial cells. Elevated epithelial SIRT1 expression is as
Regulation of lung epithelial cell senescence in smoking-induced COPD/emphysema by microR-125a-5p via Sp1 mediation of SIRT1/HIF-1a.
Chronic obstructive pulmonary disease (COPD) affects the health of more than 300 million people worldwide; at present, there is no effective drug to treat COPD. Smoking is the most important risk factor, but the molecular mechanism by which smoking causes the disease is unclear. The senescence of lung epithelial cells is related to development of COPD. Regulation of miRNAs is the main epigenetic mechanism related to aging. β-Galactose staining showed that the lung tissues of smokers have a higher degree of cellular senescence, and the expression of miR-125a-5p is high. This effect is obvious for smokers with COPD/emphysema, and there is a negative correlation between miR-125a-5p levels and values for forced expiratory volume in one second (FEV1)/forced vital capacity (FVC). After Balb/c mice were chronically exposed to various concentrations of cigarette smoke (CS), plethysmography showed that lung function was impaired, lung tissue senescence was increased, and the senescence-associat
The Role of Sirtuin 1 (SIRT1) in Neurodegeneration.
Sirtuins (SIRT) are a class of histone deacetylases that regulate important metabolic pathways and play a role in several disease processes. Of the seven mammalian homologs currently identified, sirtuin 1 (SIRT1) is the best understood and most studied. It has been associated with several neurodegenerative diseases and cancers. As such, it has been further investigated as a therapeutic target in the treatment of disorders such as Parkinson's disease (PD), Huntington's disease (HD), and Alzheimer's disease (AD). SIRT1 deacetylates histones such as H1 lysine 26, H3 lysine 9, H3 lysine 56, and H4 lysine 16 to regulate chromatin remodeling and gene transcription. The homolog has also been observed to express contradictory responses to tumor suppression and tumor promotion. Studies have shown that SIRT1 may have anti-inflammatory properties by inhibiting the effects of NF-κB, as well as stimulating upregulation of autophagy. The SIRT1 activators resveratrol and cilostazol have been shown to
SIRT1 improves lactate homeostasis in the brain to alleviate parkinsonism via deacetylation and inhibition of PKM2.
Sirtuin 1 (SIRT1) is a histone deacetylase and plays diverse functions in various physiological events, from development to lifespan regulation. Here, in Parkinson's disease (PD) model mice, we demonstrated that SIRT1 ameliorates parkinsonism, while SIRT1 knockdown further aggravates PD phenotypes. Mechanistically, SIRT1 interacts with and deacetylates pyruvate kinase M2 (PKM2) at K135 and K206, thus leading to reduced PKM2 enzyme activity and lactate production, which eventually results in decreased glial activation in the brain. Administration of lactate in the brain recapitulates PD-like phenotypes. Furthermore, increased expression of PKM2 worsens PD symptoms, and, on the contrary, inhibition of PKM2 by shikonin or PKM2-IN-1 alleviates parkinsonism in mice. Collectively, our data indicate that excessive lactate in the brain might be involved in the progression of PD. By improving lactate homeostasis, SIRT1, together with PKM2, are likely drug targets for developing agents for the t
Role of SIRT1 in autoimmune demyelination and neurodegeneration.
Multiple sclerosis (MS) is a demyelinating disease characterized by chronic inflammation of the central nervous system, in which many factors can act together to influence disease susceptibility and progression. SIRT1 is a member of the histone deacetylase class III family of proteins and is an NAD(+)-dependent histone and protein deacetylase. SIRT1 can induce chromatin silencing through the deacetylation of histones and plays an important role as a key regulator of a wide variety of cellular and physiological processes including DNA damage, cell survival, metabolism, aging, and neurodegeneration. It has gained a lot of attention recently because many studies in animal models of demyelinating and neurodegenerative diseases have shown that SIRT1 induction can ameliorate the course of the disease. SIRT1 expression was found to be decreased in the peripheral blood mononuclear cells of MS patients during relapses. SIRT1 represents a possible biomarker of relapses and a potential new target
Targeting the core of neurodegeneration: FoxO, mTOR, and SIRT1.
The global increase in lifespan noted not only in developed nations, but also in large developing countries parallels an observed increase in a significant number of non-communicable diseases, most notable neurodegenerative disorders. Neurodegenerative disorders present a number of challenges for treatment options that do not resolve disease progression. Furthermore, it is believed by the year 2030, the services required to treat cognitive disorders in the United States alone will exceed $2 trillion annually. Mammalian forkhead transcription factors, silent mating type information regulation 2 homolog 1 (Saccharomyces cerevisiae), the mechanistic target of rapamycin, and the pathways of autophagy and apoptosis offer exciting avenues to address these challenges by focusing upon core cellular mechanisms that may significantly impact nervous system disease. These pathways are intimately linked such as through cell signaling pathways involving protein kinase B and can foster, sometimes in
SIRT1 and SIRT2: emerging targets in neurodegeneration.
Sirtuins are NAD-dependent protein deacetylases known to have protective effects against age-related diseases such as cancer, diabetes, cardiovascular and neurodegenerative diseases. In mammals, there are seven sirtuins (SIRT1-7), which display diversity in subcellular localization and function. While SIRT1 has been extensively investigated due to its initial connection with lifespan extension and involvement in calorie restriction, important biological and therapeutic roles of other sirtuins have only recently been recognized. Here, we review the potential roles and effects of SIRT1 and SIRT2 in neurodegenerative diseases. We discuss different functions and targets of SIRT1 and SIRT2 in a variety of neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD) and Huntington's Disease (HD). We also cover the role of SIRT1 in neuronal differentiation due to the possible implications in neurodegenerative conditions, and conclude with an outlook on the potential
Reducing acetylated tau is neuroprotective in brain injury.
Traumatic brain injury (TBI) is the largest non-genetic, non-aging related risk factor for Alzheimer's disease (AD). We report here that TBI induces tau acetylation (ac-tau) at sites acetylated also in human AD brain. This is mediated by S-nitrosylated-GAPDH, which simultaneously inactivates Sirtuin1 deacetylase and activates p300/CBP acetyltransferase, increasing neuronal ac-tau. Subsequent tau mislocalization causes neurodegeneration and neurobehavioral impairment, and ac-tau accumulates in the blood. Blocking GAPDH S-nitrosylation, inhibiting p300/CBP, or stimulating Sirtuin1 all protect mice from neurodegeneration, neurobehavioral impairment, and blood and brain accumulation of ac-tau after TBI. Ac-tau is thus a therapeutic target and potential blood biomarker of TBI that may represent pathologic convergence between TBI and AD. Increased ac-tau in human AD brain is further augmented in AD patients with history of TBI, and patients receiving the p300/CBP inhibitors salsalate or difl
AMPK/SIRT1/PGC-1α Signaling Pathway: Molecular Mechanisms and Targeted Strategies From Energy Homeostasis Regulation to Disease Therapy.
BACKGROUND: The AMPK/SIRT1/PGC-1α pathway serves as a central regulator of cellular energy homeostasis, coordinating metabolic stress responses, epigenetic modifications, and transcriptional programs. Its dysfunction is implicated in the pathogenesis of a wide spectrum of complex modern diseases, spanning neurodegeneration, metabolic syndromes, and chronic inflammatory conditions. This review examines the pathway's role as an integrative hub and its potential as a therapeutic target. METHODS: We synthesize current mechanistic evidence from molecular, cellular, and preclinical studies to elucidate the pathway's operational logic and the consequences of its dysregulation. The analysis is structured around key disease paradigms-including Alzheimer's disease, Parkinson's disease, diabetes, cardiovascular injury, stroke, and chronic kidney disease-to dissect its tissue-specific pathophysiological impacts. RESULTS: The AMPK/SIRT1/PGC-1α axis operates through a core positive feedback loop: AM
NAD+ subcellular partitioning mediated by miR-183 and miR-96 regulates muscle stem cell differentiation.
The intracellular abundance of NAD+, a vital metabolic cofactor, critically influences muscle stem cell (MuSC) function. However, the spatial regulation of NAD+ and its impact on MuSC function remain unclear. In this study, we demonstrated that the loss of miR-183 and miR-96 leads to inefficient skeletal muscle regeneration upon injury and triggers premature differentiation of MuSC-derived primary myoblasts. The underlying mechanism involves miRNA-mediated regulation through targeting SLC25A51, a mitochondrial transporter for NAD+ that elevates mitochondrial NAD+ while reducing cytoplasmic NAD+ levels. Our results suggest that the reduction in cytoplasmic NAD+ diminishes SIRT1-mediated deacetylation, increasing H4K16ac at the promoters of myogenic genes to promote differentiation. Concurrently, the mitochondrial NAD+ accumulation stimulates the tricarboxylic acid cycle, leading to elevated levels of ATP and citrate. These metabolites allosterically activate the ACLY pathway, which in t
All the Way: A Decade of SIRT1 in Breast Cancer.
Breast cancer (BC) is a highly heterogeneous genetic disease, comprising several subtypes with distinct features that significantly influence prognosis and treatment outcomes. Among these subtypes, triple-negative breast cancer (TNBC) is particularly aggressive and makes it resistant to many standard therapies. Epigenetic mechanisms, including acetylation and deacetylation, are crucial in regulating gene expression and maintaining normal cellular functions and are closely associated with BC progression. In this context, the histone deacetylases sirtuins (SIRT1-7) regulate key biological processes like genomic stability, inflammation, cellular senescence, and metabolic functions, increasingly linked to cancer. In particular, SIRT1 shows dual roles, functioning both as a tumor suppressor or an oncogene, contributing to cancer initiation, progression, and metastasis as well as chemotherapy resistance. Despite extensive research in the past decade, the exact role of SIRT1 in BC, especially
Urolithin A Reverses Intranigral Rotenone-Generated Parkinsonism by Modulating DNA Methyltransferase 1 and α-Synuclein Axis in Rats.
Epigenetic aberrations play a key role in the neuropathogenesis of Parkinson's disease (PD). Herein, we explored the post-translational changes of DNA methyltransferase 1 (DNMT1), an epigenetic marker, in a rotenone model of PD. Rats infused with intranigral rotenone showed impaired locomotor activity and motor coordination in open-field, rotarod, and gait assays. We also noted a depression-like phenotype in the forced swim test (FST). These rotenone-generated motor and nonmotor abnormalities were reversed following peroral administration of urolithin A (UA) at 50 and 100 mg/kg doses. At the molecular level, decreased mRNA/protein expression of the NAD+-dependent sirtuin 1 (SIRT1) enzyme was seen in the substantia nigra (SN) of the rotenone-infused group. At the epigenetic level, we observed a decreased expression of DNMT1 and upregulated levels of acetylated DNMT1 (ac-DNMT1) in the SN of rotenone-recipient rats. UA treatment elevated the SIRT1 expression and DNMT1 deacetylation in the
Uncovering the metabolic-epigenetic links between gene expression and stroke: insights from lactylation pathway MR study.
BACKGROUND: Lactylation, a novel post-translational modification driven by lactate accumulation, has been implicated in neuroinflammation and metabolic stress. However, its causal relevance to ischemic stroke (IS) and its subtypes—large artery stroke (LAS), cardioembolic stroke (CES), and small vessel stroke (SVS)—remains unknown. METHODS: We conducted a two-sample Mendelian randomization (TSMR) analysis to investigate the causal relationships between lactylation-associated gene expression and IS risk. Lactylation-related genes were identified from a recent literature review and intersected with eQTL data from the eQTLGen Consortium (n = 31,684). Summary statistics for IS and its subtypes were obtained from large-scale GWAS (total cases = 62,100; controls = 1,234,808). Primary analyses used the inverse-variance weighted (IVW) method, complemented by MR-Egger, weighted median, and sensitivity tests to assess heterogeneity and pleiotropy. RESULTS: A total of 15 genes and 274 single nucle
Immune-metabolic positive feedback model in COPD: cross-mechanisms and potential intervention strategies.
Chronic obstructive pulmonary disease (COPD) is a common chronic condition characterized by chronic bronchitis and/or emphysema with airflow obstruction, which can progress to cor pulmonale and respiratory failure. Associated with abnormal inflammatory responses to harmful gases and particulate matter, it carries high rates of disability and mortality, with a global prevalence among individuals aged 40 and older reaching 9%-10%. It is often regarded as a clinical and molecular model of accelerated lung aging. Age-related drift in immune function and metabolism plays a central part in this process, but how these changes are linked across different biological levels is still not fully clarified. Current work highlights mitochondrial injury and excessive reactive oxygen species as a central node that disrupts energy-sensing pathways, interferes with autophagy and epigenetic control, and weakens mitochondrial biogenesis, together fostering long-term glycolipid imbalance. At the same time,
Demonstrates how bioactive natural products can modulate autophagy through mechanisms consistent with SIRT1-mediated nutrient sensing pathways.
Autophagy is an evolutionarily preserved intracellular degradation process pivotal in maintaining proteostasis, mitochondrial homeostasis, and metabolic equilibrium, all of which are dysregulated with aging. Aberrant autophagy has been recognized as a hallmark of human aging and age-related diseases, including neurodegeneration, metabolic dysfunction, cardiovascular diseases, and cancer. Bioactive natural compounds derived from plants, foods, and marine organisms have emerged as potent modulator
Validates oxidative stress-related regulatory genes that align with the hypothesis's focus on SIRT1-mediated metabolic regulation in neurodegeneration.
Oxidative stress (OS) plays a critical role in the pathogenesis of Alzheimer's disease (AD), yet its genetic and epigenetic regulatory mechanisms remain unclear. In this study, we applied a three-step summary-based Mendelian randomization (SMR) framework to integrate Alzheimer's disease (AD) GWAS summary statistics with peripheral-blood eQTL and mQTL datasets, and further evaluated brain-tissue relevance using GTEx v8 and AMP-AD resources. Across the three-step SMR analyses, we prioritized multi
Provides direct evidence of SIRT1-driven mitochondrial biogenesis as a neuroprotective mechanism in neurological injury models.
Chronic cerebral ischemia (CCI) induces hippocampal neuronal injury, with mitochondrial dysfunction emerging as a pivotal pathological driver of ischemic brain damage. Enhancing mitochondrial biogenesis (MB) represents a promising reparative strategy to restore neuronal homeostasis. Rhodiola sacra (RS), a traditional Tibetan herb, exhibits neuroprotective potential against ischemic injury; however, its underlying mechanisms, particularly its association with MB, remain unclear. This study aims t
Explores insulin resistance and SIRT1 dysregulation, directly supporting the hypothesis's core mechanism of nutrient-sensing circuit disruption.
Metabolic diseases such as Type 2 Diabetes, obesity, and metabolic syndrome are increasing worldwide in parallel with neurodegenerative disorders, yet a unifying biological framework linking systemic metabolic dysfunction to progressive neuronal loss is still lacking. Existing models remain fragmented, focusing on disease-specific mechanisms rather than the shared metabolic vulnerability of the brain. Here, we propose an insulin resistance-Sirtuin 1 collapse axis as a unifying metabolic paradigm
Highlights dysregulation of SIRT1 in aging and cancer, supporting the hypothesis's central mechanism.
Interest in RNA editing has emerged in molecular medicine due to its widespread dysregulation and therapeutic potential. Its regulatory mechanisms in governing non-coding RNAs, especially microRNAs (miRNAs) remain largely unresolved. Emerging evidence in diseases reveals a functional convergence between miRNAs and polyamine metabolism, two systems traditionally studied separately. miRNAs serve as primary substrates for adenosine deaminase acting on RNA (ADAR) which could regulate polyamine metab
Investigates sirtuin/FOXO3a cascade in Alzheimer's disease, directly aligning with the proposed nutrient-sensing regulatory network.
Sulfonamide-based compounds have been a clinically attractive scaffold for drug development and proven as antioxidant and antimicrobial agents, but their pharmacological derivatives containing anthranilates (SA1-4) and therapeutic targets are not clearly clarified. To unravel the neuroprotective roles and underlying mechanisms of SA1-4 against oxidative injury and healthy longevity crosstalk, a combination of in vitro experiments, in silico modeling, and network pharmacology was employed. Pretre
The paper demonstrates linkages between mitochondrial-epigenetic networks and cellular survival, supporting the hypothesis's core mechanism of metabolic regulation through epigenetic circuits.
Sirtuins (SIRT1-SIRT7) are NAD⁺-dependent regulators of mitochondrial metabolism, chromatin remodeling, and stress resilience pathways-processes that are central to both aging biology and breast cancer (BC) heterogeneity. We systematically evaluated their prognostic and transcriptional patterns across molecular subtypes of BC. We constructed an integrated BC dataset comprising gene expression and survival data containing tumors from 55 datasets. Prognostic associations with recurrence-free survi
Mechanistic advances in exercise‑mediated regulation of autophagy dysfunction in Alzheimer's disease (Review).
Valsartan promotes neuroprotection in Parkinson's disease via epigenetic modulation and activation of the ASCL1/Nurr1 pathway.
SIRT1 Activators as Geroprotective Agents in Brain Aging: Mechanisms and Therapeutic Potential.
Loss of REST associated with Alzheimer's disease pathology is ameliorated by NAD.
[The Chinese medicine Gandouling attenuates brain injury in hepatolenticular degeneration mice by inhibiting ferroptosis via the SIRT1/FoxO3 pathway].
Unravelling the therapeutic potential of chrysin against ischemic stroke and post-stroke cognitive impairment: a network pharmacology and in-silico perspective.
Evidence against (9)
Exercise orchestrates systemic metabolic and neuroimmune homeostasis via the brain-muscle-liver axis to slow down aging and neurodegeneration: a narrative review
Aging is a systemic process marked by progressive multi-organ dysfunction, metabolic dysregulation, and chronic low-grade inflammation ("inflammaging"), which collectively drive neurodegenerative diseases such as Alzheimer's Disease (AD) and Parkinson's Disease (PD). Emerging evidence underscores the brain-muscle-liver axis as a central hub for maintaining energy homeostasis and neuroimmune crosstalk during aging. Here, we elucidate how exercise orchestrates inter-organ communication to counteract age-related decline through metabolic reprogramming, immunomodulation, and neuroprotection. Mechanistically, exercise enhances mitochondrial biogenesis and oxidative capacity in skeletal muscle via AMPK/PGC-1α signaling, restoring fatty acid oxidation and glucose metabolism while producing myokines (e.g., BDNF and IL-6) that promote neuronal survival and synaptic plasticity. Concurrently, hepatic SIRT1 activation promotes lipid metabolism, mitigates insulin resistance, and reduces systemic in
Nicotinamide N-methyltransferase as a potential therapeutic target for neurodegenerative disorders: Mechanisms, challenges, and future directions
Neurodegenerative diseases (NDs), including Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD), are characterized by progressive neuronal loss and functional decline, posing significant global health challenges. Emerging evidence highlights nicotinamide N-methyltransferase (NNMT), a cytosolic enzyme regulating nicotinamide (NAM) methylation, as a pivotal player in NDs through its dual impact on epigenetic regulation and metabolic homeostasis. This review synthesizes current knowledge on NNMT's role in disease pathogenesis, focusing on its epigenetic modulation via DNA hypomethylation and histone modifications, alongside its disruption of NAD+ synthesis and homocysteine (Hcy) metabolism. Elevated NNMT activity depletes NAD+, exacerbating mitochondrial dysfunction and impairing energy metabolism, while increased Hcy levels drive oxidative stress, neuroinflammation, and aberrant protein aggregation (e.g., Aβ, tau, α-synuclein). Notably, NNMT overexpression i
Protective effects of CHIP overexpression and Wharton's jelly mesenchymal-derived stem cell treatment against streptozotocin-induced neurotoxicity in rats
Diabetic neuropathy is a common complication of diabetes mellitus, posing a challenge in treatment. Previous studies have indicated the protective role of mesenchymal stem cells against several disorders. Although they can repair nerve injury, their key limitation is that they reduce viability under stress conditions. We recently observed that overactivation of the carboxyl terminus of heat shock protein 70 (Hsp70) interacting protein (CHIP) considerably rescued cell viability under hyperglycemic stress and played an essential role in promoting the beneficial effects of Wharton's jelly-derived mesenchymal stem cells (WJMSCs). Thus, the present study was designed to unveil the protective effects of CHIP-overexpressing WJMSCs against neurodegeneration using in vivo animal model based study. In this study, western blotting observed that CHIP-overexpressing WJMSCs could rescue nerve damage observed in streptozotocin-induced diabetic rats by activating the AMPKα/AKT and PGC1α/SIRT1 signalin
Mammalian nucleophagy: process and function.
The nucleus is a highly specialized organelle that houses the cell's genetic material and regulates key cellular activities, including growth, metabolism, protein synthesis, and cell division. Its structure and function are tightly regulated by multiple mechanisms to ensure cellular integrity and genomic stability. Increasing evidence suggests that nucleophagy, a selective form of autophagy that targets nuclear components, plays a critical role in preserving nuclear integrity by clearing dysfunctional nuclear materials such as nuclear proteins (lamins, SIRT1, and histones), DNA-protein crosslinks, micronuclei, and chromatin fragments. Impaired nucleophagy has been implicated in aging and various pathological conditions, including cancer, neurodegeneration, autoimmune disorders, and neurological injury. In this review, we focus on nucleophagy in mammalian cells, discussing its mechanisms, regulation, and cargo selection, as well as evaluating its therapeutic potential in promoting human
Hippocampus and its involvement in Alzheimer's disease: a review.
Hippocampus is the significant component of the limbic lobe, which is further subdivided into the dentate gyrus and parts of Cornu Ammonis. It is the crucial region for learning and memory; its sub-regions aid in the generation of episodic memory. However, the hippocampus is one of the brain areas affected by Alzheimer's (AD). In the early stages of AD, the hippocampus shows rapid loss of its tissue, which is associated with the functional disconnection with other parts of the brain. In the progression of AD, atrophy of medial temporal and hippocampal regions are the structural markers in magnetic resonance imaging (MRI). Lack of sirtuin (SIRT) expression in the hippocampal neurons will impair cognitive function, including recent memory and spatial learning. Proliferation, differentiation, and migrations are the steps involved in adult neurogenesis. The microglia in the hippocampal region are more immunologically active than the other regions of the brain. Intrinsic factors like hormon
Role of advanced glycation end products in cellular signaling.
Improvements in health care and lifestyle have led to an elevated lifespan and increased focus on age-associated diseases, such as neurodegeneration, cardiovascular disease, frailty and arteriosclerosis. In all these chronic diseases protein, lipid or nucleic acid modifications are involved, including cross-linked and non-degradable aggregates, such as advanced glycation end products (AGEs). Formation of endogenous or uptake of dietary AGEs can lead to further protein modifications and activation of several inflammatory signaling pathways. This review will give an overview of the most prominent AGE-mediated signaling cascades, AGE receptor interactions, prevention of AGE formation and the impact of AGEs during pathophysiological processes.
Microglial Activation Under Hypoxic Conditions in Early Alzheimer's Disease: Can Natural SIRT1 Activators Be Therapeutic Allies in the Inflammation-Energy Axis?
Alzheimer's disease (AD) is a progressive neurodegenerative condition characterized by a preclinical stage that typically lasts for decades. Early on during this time, microglia react to pathological changes and become protective and even transiently delay neurodegeneration. In contrast, microglia later acquire the typical pro-inflammatory features that contribute to neurodegeneration in advanced disease. Such decades-long time frame is marked by a significant vulnerability to any event able to tip the balance toward inflammatory microglia. Increasing evidence suggests that early life hypoxic events could be risk factors for AD by acting as early triggers of microglial phenotypic transition, especially affecting mitochondrial functions and energy balance. The NAD+-dependent deacetylase SIRT1 could be a valuable target in this context for its anti-inflammatory and anti-aging functions, which include direct modulation of mitochondrial homeostasis. Many natural compounds enriched in Medit
Therapeutic potential of sulforaphane in neurodegenerative diseases: mechanistic Insights into Nrf2, NF-κB, TrkB, SIRT1, MAPK, and JAK/STAT signalling pathways.
Advances and Therapeutic Potential of Anthraquinone Compounds in Neurodegenerative Diseases: A Comprehensive Review.
BACKGROUND: Rhubarb, traditionally used in China for neurological disorders, has recently attracted considerable scientific attention for its neuroprotective and cerebrovascular benefits. The main therapeutic components of rhubarb are anthraquinones, including emodin, aloe-emodin, chrysophanol, rhein, and physcion. Accumulating experimental evidence indicates that anthraquinones are of importance in neurodegenerative diseases (NDDs), such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and multiple sclerosis. However, as a promising candidate for drug development, the mechanisms by which anthraquinones treat NDDs have not been systematically reviewed. Therefore, this article outlines the anti-neurodegenerative effects of anthraquinones, focusing on their molecular mechanisms. OBJECTIVE: This article reviews recent research progress of anthraquinones in NDDs, focusing on their potential targets and pathways to provide new ideas for the intervention and treatment of ND
Evidence matrix
Supporting
- Caloric restriction improves cognitive performance and restores circadian patterns of neurotrophic, clock, and epigenetic factors PMID:39447038 · 2024 · J Gerontol A Biol Sci Med Sci
- Sirtuin modulators have established therapeutic potential PMID:21879453 · 2011 · Handb Exp Pharmacol
- HDAC inhibitors show promise for healthy aging PMID:31368626 · 2019 · EMBO Mol Med
- Memorable food interventions can fight age-related neurodegeneration through precision nutrition PMID:34422879 · 2021 · Front Nutr
- Sirtuin family in autoimmune diseases. PMID:37483618 · 2023 · Front Immunol
- PTBP1 Lactylation Promotes Glioma Stem Cell Maintenance through PFKFB4-Driven Glycolysis. PMID:39570804 · 2025 · Cancer Res
- Fasting and fasting-mimicking treatment activate SIRT1/LXRα and alleviate diabetes-induced systemic and microvascular dysfunction. PMID:33770194 · 2021 · Diabetologia
- Innate Immune Training Initiates Efferocytosis to Protect against Lung Injury. PMID:38279580 · 2024 · Adv Sci (Weinh)
- Regulation of lung epithelial cell senescence in smoking-induced COPD/emphysema by microR-125a-5p via Sp1 mediation of SIRT1/HIF-1a. PMID:35002516 · 2022 · Int J Biol Sci
- The Role of Sirtuin 1 (SIRT1) in Neurodegeneration. PMID:37456463 · 2023 · Cureus
- SIRT1 improves lactate homeostasis in the brain to alleviate parkinsonism via deacetylation and inhibition of PKM2. PMID:39128469 · 2024 · Cell Rep Med
- Role of SIRT1 in autoimmune demyelination and neurodegeneration. PMID:25281273 · 2015 · Immunol Res
- Targeting the core of neurodegeneration: FoxO, mTOR, and SIRT1. PMID:32985464 · 2021 · Neural Regen Res
- SIRT1 and SIRT2: emerging targets in neurodegeneration. PMID:23417962 · 2013 · EMBO Mol Med
- Reducing acetylated tau is neuroprotective in brain injury. PMID:33852912 · 2021 · Cell
- AMPK/SIRT1/PGC-1α Signaling Pathway: Molecular Mechanisms and Targeted Strategies From Energy Homeostasis Regulation to Disease Therapy. PMID:41268687 · 2025 · CNS Neurosci Ther
- NAD+ subcellular partitioning mediated by miR-183 and miR-96 regulates muscle stem cell differentiation. PMID:41915008 · 2026 · J Mol Cell Biol
- All the Way: A Decade of SIRT1 in Breast Cancer. PMID:41898317 · 2026 · Biomedicines
- Urolithin A Reverses Intranigral Rotenone-Generated Parkinsonism by Modulating DNA Methyltransferase 1 and α-Synuclein Axis in Rats. PMID:41880654 · 2026 · ACS Chem Neurosci
- Uncovering the metabolic-epigenetic links between gene expression and stroke: insights from lactylation pathway MR study. PMID:41877258 · 2026 · Neurol Res Pract
- Immune-metabolic positive feedback model in COPD: cross-mechanisms and potential intervention strategies. PMID:41869013 · 2026 · Front Cell Dev Biol
- Demonstrates how bioactive natural products can modulate autophagy through mechanisms consistent with SIRT1-mediated nutrient sensing pathways. PMID:41830033 · 2026 · Nutrients
- Validates oxidative stress-related regulatory genes that align with the hypothesis's focus on SIRT1-mediated metabolic regulation in neurodegeneration. PMID:41844011 · 2026 · J Prev Alzheimers Dis
- Provides direct evidence of SIRT1-driven mitochondrial biogenesis as a neuroprotective mechanism in neurological injury models. PMID:41879438 · 2026 · Curr Neuropharmacol
- Explores insulin resistance and SIRT1 dysregulation, directly supporting the hypothesis's core mechanism of nutrient-sensing circuit disruption. PMID:41759326 · 2026 · Ageing Res Rev
- Highlights dysregulation of SIRT1 in aging and cancer, supporting the hypothesis's central mechanism. PMID:41863647 · 2026 · Amino Acids
- Investigates sirtuin/FOXO3a cascade in Alzheimer's disease, directly aligning with the proposed nutrient-sensing regulatory network. PMID:41714304 · 2026 · J Neurochem
- The paper demonstrates linkages between mitochondrial-epigenetic networks and cellular survival, supporting the hypothesis's core mechanism of metabolic regulation through epigenetic circuits. PMID:41692938 · 2026 · Geroscience
- Mechanistic advances in exercise‑mediated regulation of autophagy dysfunction in Alzheimer's disease (Review). PMID:41645754 · 2026 · Int J Mol Med
- Valsartan promotes neuroprotection in Parkinson's disease via epigenetic modulation and activation of the ASCL1/Nurr1 pathway. PMID:41936814 · 2026 · Life Sci
- SIRT1 Activators as Geroprotective Agents in Brain Aging: Mechanisms and Therapeutic Potential. PMID:41934491 · 2026 · Neuromolecular Med
- Loss of REST associated with Alzheimer's disease pathology is ameliorated by NAD. PMID:41709697 · 2026 · Brain
- [The Chinese medicine Gandouling attenuates brain injury in hepatolenticular degeneration mice by inhibiting ferroptosis via the SIRT1/FoxO3 pathway]. PMID:41946579 · 2026 · Zhejiang Da Xue Xue Bao Yi Xue Ban
- Unravelling the therapeutic potential of chrysin against ischemic stroke and post-stroke cognitive impairment: a network pharmacology and in-silico perspective. PMID:41687709 · 2026 · Neuroscience
Contradicting
- Exercise orchestrates systemic metabolic and neuroimmune homeostasis via the brain-muscle-liver axis to slow down aging and neurodegeneration: a narrative review PMID:40506775 · 2025 · Eur J Med Res
- Nicotinamide N-methyltransferase as a potential therapeutic target for neurodegenerative disorders: Mechanisms, challenges, and future directions PMID:40221009 · 2025 · Exp Neurol
- Protective effects of CHIP overexpression and Wharton's jelly mesenchymal-derived stem cell treatment against streptozotocin-induced neurotoxicity in rats PMID:35442559 · 2022 · Environ Toxicol
- Mammalian nucleophagy: process and function. PMID:39827882 · 2025 · Autophagy
- Hippocampus and its involvement in Alzheimer's disease: a review. PMID:35116217 · 2022 · 3 Biotech
- Role of advanced glycation end products in cellular signaling. PMID:24624331 · 2014 · Redox Biol
- Microglial Activation Under Hypoxic Conditions in Early Alzheimer's Disease: Can Natural SIRT1 Activators Be Therapeutic Allies in the Inflammation-Energy Axis? PMID:41902653 · 2026 · Phytother Res
- Therapeutic potential of sulforaphane in neurodegenerative diseases: mechanistic Insights into Nrf2, NF-κB, TrkB, SIRT1, MAPK, and JAK/STAT signalling pathways. PMID:41894075 · 2026 · Mol Biol Rep
- Advances and Therapeutic Potential of Anthraquinone Compounds in Neurodegenerative Diseases: A Comprehensive Review. PMID:41868184 · 2026 · Drug Des Devel Ther
Cite this hypothesis
Cite this hypothesis
etl-backfill (2026). Metabolic NAD+ Salvage Pathway Enhancement Through NAMPT Overexpression. SciDEX hypothesis. https://prism.scidex.ai/hypotheses/h-var-159030513d
@misc{scidex_hypothesis_hvar1590,
title = {Metabolic NAD+ Salvage Pathway Enhancement Through NAMPT Overexpression},
author = {etl-backfill},
year = {2026},
howpublished = {SciDEX hypothesis},
url = {https://prism.scidex.ai/hypotheses/h-var-159030513d},
note = {SciDEX artifact hypothesis:h-var-159030513d}
}